Tags

Type your tag names separated by a space and hit enter

Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective.
Diabetes Ther. 2020 Apr; 11(4):1029-1043.DT

Abstract

The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting.

Authors+Show Affiliations

Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.Third Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.First Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary.1st. Department of Endocrinology, Békés County Central Hospital, Dr Réthy Pál Member Hospital, Békéscsaba, Hungary.Romania National Institute of Diabetes, Nutrition and Metabolic Diseases "NC Paulescu", Carol Davila University of Medicine and Pharmacy, Bucharest, Bucharest, Romania.Unit of Diabetes, Nutrition and Metabolic Diseases, "Grigore T. Popa" University of Medicine and Pharmacy, Iaşi, Romania. "Sf. Spiridon" Emergency Hospital, Iaşi, Romania.Clinical Center of Diabetes, Nutrition, Metabolic Diseases, Cluj-Napoca, Romania.National Institute for Endocrinology and Diabetology, Lubochna, Slovak Republic.Syreon Research Institute, Budapest, Hungary. gabor.kovacs@syreon.eu.First Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32144742

Citation

Haluzík, Martin, et al. "Expert Opinion On the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, vol. 11, no. 4, 2020, pp. 1029-1043.
Haluzík M, Flekač M, Lengyel C, et al. Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. Diabetes Ther. 2020;11(4):1029-1043.
Haluzík, M., Flekač, M., Lengyel, C., Taybani, Z., Guja, C., Mihai, B. M., Cerghizan, A., Martinka, E., Kovacs, G., & Kempler, P. (2020). Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 11(4), 1029-1043. https://doi.org/10.1007/s13300-020-00777-2
Haluzík M, et al. Expert Opinion On the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. Diabetes Ther. 2020;11(4):1029-1043. PubMed PMID: 32144742.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. AU - Haluzík,Martin, AU - Flekač,Milan, AU - Lengyel,Csaba, AU - Taybani,Zoltán, AU - Guja,Cristian, AU - Mihai,Bogdan-Mircea, AU - Cerghizan,Anca, AU - Martinka,Emil, AU - Kovacs,Gabor, AU - Kempler,Péter, Y1 - 2020/03/06/ PY - 2019/12/23/received PY - 2020/3/8/pubmed PY - 2020/3/8/medline PY - 2020/3/8/entrez KW - Expert opinion KW - Fixed-ratio combination KW - Insulin glargine and lixisenatide SP - 1029 EP - 1043 JF - Diabetes therapy : research, treatment and education of diabetes and related disorders JO - Diabetes Ther VL - 11 IS - 4 N2 - The fixed-ratio combination (FRC) of a basal insulin and a GLP-1 receptor agonist (GLP-1 RA) has proven to be an effective therapeutic approach. However, physicians face numerous practical questions that cannot be answered by recently published trial results, current guidelines and summaries of product characteristics. In April 2019, a scientific meeting was held with the participation of nine experts from four Central and Eastern European countries to provide expert consensus on the optimal daily use of the insulin glargine and lixisenatide FRC (iGlarLixi). Topics included the positioning and initiation of iGlarLixi and the management of treatment. This paper summarizes the outcomes of the meeting. SN - 1869-6953 UR - https://www.unboundmedicine.com/medline/citation/32144742/Expert_Opinion_on_the_Therapeutic_Use_of_the_Fixed-Ratio_Combination_of_Insulin_Glargine_100_U/mL_and_Lixisenatide:_a_Central/Eastern_European_Perspective L2 - https://dx.doi.org/10.1007/s13300-020-00777-2 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.